GlassScriptPhysician profile
Osama Hlalah
NPI 1144210022
$40,136.40
in general payments reported to CMS, 2019-2025
56 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $4,673 · 2021: $9,638 · 2022: $667 · 2023: $890 · 2024: $180 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042 · Long Term Medical Supply Or Device Loan: $167 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.01 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $20,953.96 | 2019-2021 | |
| Janssen Biotech, INC. | $5,056.38 | 2019-2024 | Darzalex |
| Celgene Corporation | $3,826.37 | 2019-2023 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $2,991.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,324.78 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $590.26 | 2019-2022 | |
| Astellas Pharma US INC | $521.99 | 2019-2023 | Padcev |
| Pfizer INC. | $438.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $351.88 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $306.40 | 2019-2025 | Enhertu |
| Genzyme Corporation | $189.32 | 2019-2023 | |
| Incyte Corporation | $170.00 | 2019-2024 | Monjuvi, Jakafi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.71 | 2019-2021 | |
| Seagen INC. | $152.15 | 2019-2025 | Adcetris |
| Genentech USA, INC. | $148.97 | 2019-2021 |
Show all 54 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Hlalah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.